Orgenesis
Orgenesis is a public biotech operating a decentralized cell and gene therapy manufacturing platform, serving hospitals, biotech companies, and research institutions via its global POCare Network and proprietary mobile processing units (OMPUL).
- Company typePublic
- Founded2008
- HeadquartersWhite Plains, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Orgenesis does
Orgenesis Inc. is a publicly traded biotechnology company that operates a decentralized cell and gene therapy (CGT) manufacturing platform under the POCare brand. Founded in 2008 and headquartered in Germantown, Maryland, Orgenesis went public in August 2011 and currently trades on the OTC Expert Market under ticker ORGS after being delisted from Nasdaq, with a market valuation of approximately $1.87 million as of January 2026. The company's core function is to enable hospitals, healthcare providers, and biotechnology companies to produce advanced personalized therapies at the point of care rather than relying on centralized manufacturing infrastructure, through a network spanning the United States, Israel, Belgium, and South Korea.
The POCare Platform is built on three integrated components: POCare Therapies (a pipeline of owned, licensed, and partnered candidates including ORGCAR19, Kyslecel — which holds FDA orphan drug designation for total pancreatectomy — Bioxome exosomes, DUVAC, MOTC, and RanTop); POCare Technologies, anchored by the OMPUL (Orgenesis Mobile Processing Units and Labs), a proprietary closed-loop bioprocessing unit with Grade A/B or A/D clean room environments, automated single-use sensors, and cloud-based data connectivity; and POCare Network, a global collaborative framework spanning partner institutions in the US, Israel, Belgium, South Korea, Spain, Greece, Austria, Germany, and China. OMPUL implementation compresses typical CGT deployment timelines from 18-24 months to 3-6 months, and the Korean GMP plant supports commercial-scale manufacturing.
Orgenesis generates revenue across three primary streams: therapeutic licensing and royalties from its owned and partnered therapy pipeline, hardware sales of OMPUL processing systems, and point-of-care processing services delivered through decentralized POCare centers within a six-hour radius of patients. Its customer base spans three vertical segments — hospitals and healthcare providers (primary), biotechnology companies requiring CGT scale-up support, and academic and research institutions. The company has raised over $35 million in cumulative funding, with Metalmark Capital as the principal institutional backer. As of 2024, Orgenesis continues to report operating losses and dependence on external financing, has divested its ranpirnase portfolio to Okogen Inc. (March 2026), and has undergone leadership transitions including a new CFO (Doug Karriker) and new directors appointed in March 2026.
Orgenesis firmographics
Firmographics- Name
- Orgenesis
- Legal name
- Orgenesis Inc.
- Website
- https://orgenesis.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Orgenesis is a public biotech operating a decentralized cell and gene therapy manufacturing platform, serving hospitals, biotech companies, and research institutions via its global POCare Network and proprietary mobile processing units (OMPUL).
- Ownership category
- akta.pro rank
Orgenesis industry classification
Industry- Product category
- Cell and Gene Therapy Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)
- akta.pro secondary industry
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Orgenesis is headquartered
LocationHeadquarters
- HQ city
- White Plains
- HQ country
- United States
- HQ region
- North America
Offices7 records
Markets served
Orgenesis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Therapeutic Licensing and Royalties: By identifying and partnering with early-stage biotechnology developers, Orgenesis brings development and validation in-house to create a pipeline of owned, licensed, and partnered therapies. The company applies know-how in CGT development and production to build long-term opportunities via processing licenses and royalties at the POCare Network level.
- Technology Processing Systems: Revenue generated from customized, automated processing systems (OMPUL) that enable point-of-care production of cell and gene therapies. Systems are validated for each therapy to intensify production as high-margin scalable solutions.
- Point-of-Care Processing Services: Revenue from providing processing services through the decentralized network of POCare centers and OMPUL hubs located at hospitals and healthcare facilities globally.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Orgenesis product offering
Product offeringCore offering
Orgenesis is a biotechnology company that operates a decentralized point-of-care (POCare) platform for cell and gene therapy manufacturing and processing. The company develops therapeutic products, supplies mobile processing units and labs (OMPUL), and provides a distributed network enabling hospitals, biotech firms, and academic institutions to perform cell and gene therapy processing close to patients.
Product overview
Orgenesis offers a unified platform ecosystem centered on the POCare Platform, which integrates three core components: POCare Therapies (a pipeline of advanced cell and gene therapies), POCare Technologies (customized automated processing systems), and POCare Network (a global collaborative network). The key product is the Orgenesis Mobile Processing Units and Labs™ (OMPUL™), a fully integrated closed-loop bioprocessing unit that enables decentralized CGT manufacturing at point-of-care locations. The therapy pipeline includes named candidates such as ORGCAR19 (CD19 CAR-T), MOTC, DUVAC, RanTop, Kyslecel™, and Bioxome™ spanning immuno-oncology, viral diseases, metabolic diseases, and vascular/musculoskeletal applications. The company serves academic medical centers, hospitals, and biotechnology companies through POCare Centers that can be deployed rapidly using OMPUL™ technology.
Differentiator
Problem solved
Functional benefit
Brands
- POCare Platform: Point-of-care platform providing a pathway for unlocking the full potential of cell and gene therapies (CGTs) in an affordable and accessible format.
- OMPUL (Orgenesis Mobile Processing Units and Labs)
- POCare Therapies
- POCare Technologies
- POCare Network
- Morgenesis
Products and services
- POCare Therapies Cell and gene therapeutic products developed and supplied by Orgenesis, delivered to hospitals and clinical partners through the POCare decentralized manufacturing model.
- POCare Technologies Proprietary processing technology systems and platforms licensed or sold to partners for cell and gene therapy manufacturing at the point of care.
- POCare Network A distributed service network that connects hospitals, biotech companies, and academic institutions to enable point-of-care processing, development, and delivery of cell and gene therapies.
- OMPUL (Mobile Processing Units and Labs) Modular mobile processing units and laboratory infrastructure that Orgenesis deploys at hospital or partner sites to enable decentralized manufacturing of cell and gene therapies at the point of care.
Quantifiable outcome
- Implementation time reduced from 18-24 months to 3-6 months
- +2 more outcomes
Companies that use Orgenesis
Customer profileSegments3 records
Ideal customer profiles3 records
Orgenesis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Orgenesis partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered major and core.
- Harley Street Healthcare GroupmajorStrategic partnership to launch a global longevity and wellness initiative with an investment commitment of up to $10 million over three years. Joint venture to develop health and wellness services including regenerative therapies and preventative care, targeting multiple regions worldwide.
- BioWincoreBioWin is a consortium member of the EXOFASTTRACK project. BioWin is the health and biotech cluster of Wallonia, Belgium, supporting collaborative initiatives in therapeutic exosome development.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Orgenesis competitors and assessment
Company assessmentEmerging players
- IsoPlexis: Provides single-cell analytics platforms used in cell therapy development and manufacturing quality control. Operates in the broader cell therapy ecosystem with technology that could integrate with Orgenesis's POCare quality harmonization framework.
- CellPoint (acquired by Lonza): Developed point-of-care CAR-T manufacturing technology that was acquired by Lonza in 2022, validating the decentralized manufacturing thesis but now competing under Lonza's broader CDMO portfolio against Orgenesis.
Direct peers
- Cellares: Direct competitor in decentralized cell therapy manufacturing with its Cell Shuttle platform—an automated, closed-system manufacturing solution aimed at scaling cell therapy production. Competes head-to-head with Orgenesis's OMPUL for biotech and hospital customers.
- Vineti: Provides cell and gene therapy orchestration software and supply chain management for therapy developers and treatment centers. Complementary/competing with Orgenesis's POCare Network by enabling CGT delivery to patients at point-of-care.
Broad incumbents
- Lonza: Global CDMO leader offering cell and gene therapy manufacturing services including viral vectors, autologous/allogeneic cell therapies, and biologics. Operates large-scale centralized facilities that compete with Orgenesis's decentralized POCare model for the same biotech customers.
- Gilead Sciences (Kite Pharma): Operates Kite Pharma, a leading CAR-T manufacturer (Yescarta, Tecartus). Competes in the same autologous cell therapy commercial space where Orgenesis is building its decentralized production capabilities.
- AGC Biologics: Global CDMO with cell and gene therapy manufacturing services including autologous and allogeneic cell therapy production. Competes with Orgenesis for biotech customers requiring GMP-compliant CGT manufacturing capacity.
- Catalent: Major CDMO with cell therapy manufacturing capabilities serving gene therapy and CAR-T developers. Its Paragon Gene Therapy and cell therapy services overlap with Orgenesis's POCare platform for biotech clients needing manufacturing scale-up.
- Novartis: Pharma company that pioneered commercial CAR-T therapy (Kymriah) and operates large-scale cell therapy manufacturing. Represents both a potential OMPUL/POCare customer and a competitive threat in autologous cell therapy commercialization.
- Thermo Fisher Scientific (Patheon): Operates a global CDMO business with dedicated cell and gene therapy manufacturing services. Competes with Orgenesis for biotech customers needing commercial-scale production of advanced therapies and offers integrated clinical trial material supply.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Orgenesis social profiles
Digital presenceOrgenesis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Orgenesis leadership team
Management profileNumber of profiles
Profiles1 record
Orgenesis subsidiaries and ownership
Company hierarchySubsidiaries5 records
Orgenesis funding detail
Funding detailFunding overview
Funding rounds9 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Orgenesis M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Orgenesis
What does Orgenesis do?
Orgenesis is a biotechnology company that operates a decentralized point-of-care (POCare) platform for cell and gene therapy manufacturing and processing. The company develops therapeutic products, supplies mobile processing units and labs (OMPUL), and provides a distributed network enabling hospitals, biotech firms, and academic institutions to perform cell and gene therapy processing close to patients.
Is Orgenesis a public or private company?
Orgenesis is a public company. It is classified as public and is currently operating.
When was Orgenesis founded?
Orgenesis was founded in 2008. It employs 101 to 250 people.
Where is Orgenesis based?
Orgenesis is headquartered in White Plains, United States, in the North America region.
How does Orgenesis make money?
Three revenue lines are on record. Therapeutic Licensing and Royalties are the primary driver. The others are technology Processing Systems and point-of-Care Processing Services.
Who are Orgenesis's main competitors?
Emerging players on record are IsoPlexis and CellPoint (acquired by Lonza). Direct peers are Cellares and Vineti. Broad incumbents are Lonza, Gilead Sciences (Kite Pharma), AGC Biologics, Catalent, Novartis and Thermo Fisher Scientific (Patheon).
Does Orgenesis have an API?
No public API is recorded for Orgenesis.
What industry is Orgenesis in?
Orgenesis's product category is Cell and Gene Therapy Manufacturing. Its primary akta.pro industry code is HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing), with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325414 and its SIC code is 2834.